Grants and Contributions:
Title:
Development of a Treatment for COVID-19
Agreement Number:
953967
Agreement Value:
$334,359.93
Agreement Date:
Jun 1, 2020 - May 31, 2022
Description:
Orion Biotechnology is developing a novel biologic for the treatment of SARS-CoV-2.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Ottawa, Ontario, CA K1S 1N4
Reference Number:
172-2020-2021-Q2-953967
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
708721493
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by -30 days. The total amended value is -41,808.07 dollars.
Amendment Date
Jul 12, 2022
Recipient's Legal Name:
Orion Biotechnology Canada Ltd.
Federal Riding Name:
Ottawa Centre
Federal Riding Number:
35075
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: